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Introduction: Adenocarcinoma of the seminal vesicles is a very rare malignancy, with less than 100 cases reported
worldwide. It is documented to have a poor prognosis, with the majority of patients developing metastatic disease,
most commonly in the prostate, bladder and rectum. Currently there is no standard treatment for metastatic
disease and the limited reports of treatment with radiotherapy, chemotherapy and hormonal (anti-androgenic)
therapy show that they are generally of modest benefit. The association between malignancy and an increased risk
of autoimmune vasculitis has been demonstrated in a number of malignancies, but to date there have been no
documented cases of adenocarcinoma of the seminal vesicles associated with anti-neutrophil cytoplasmic antibody
vasculitis.
Case presentation: In this report we describe the case of a 55-year-old Caucasian man with metastatic
adenocarcinoma of the seminal vesicles. He previously had received chemotherapy treatment for advanced
testicular cancer and later presented with hemospermia. He subsequently developed c-antineutrophil cytoplasmic
antibody vasculitis requiring intensive immunosuppression and renal dialysis.
Conclusion: Adenocarcinoma of the seminal vesicles is a rare diagnosis and our case is more unusual in that our
patient previously had chemotherapy treatment for advanced testicular cancer and went on to develop severe
antineutrophil cytoplasmic antibody vasculitis when diagnosed with metastatic seminal vesicle cancer. This case
illustrates that autoimmune vasculitis can occur in any patient with malignancy and an early referral to the renal
team combined with renal biopsy can assist in the earlier diagnosis and more successful management of these rare
events. This case should be of interest to oncologists, renal physicians, urologists and general physicians who
encounter patients presenting with hemospermia or vasculitis.Introduction
Adenocarcinoma of the seminal vesicles is a very rare
malignancy, with fewer than 100 cases reported world-
wide [1-7]. There have been no clear etiological factors
demonstrated. The malignancy characteristically pre-
sents with either obstructive uropathy or hematuria with
the imaging demonstrating tumor masses in the seminal
vesicles. On radiology it is difficult to distinguish primary
carcinoma of the seminal vesicles from a local invasion
from prostate cancer. However, the immunohistochemistry* Correspondence: philip.savage@imperial.nhs.uk
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reproduction in any medium, provided the orof seminal vesicle carcinoma is characterized by positive
staining for cancer antigen 125 (CA-125) and cytokeratin
(CK)-7 and a lack of expression of membrane prostate-
specific antigen, which helps differentiate the rare diagnosis
of seminal vesicle carcinoma from the more frequent cases
of prostatic cancer invading the seminal vesicles [4]. Serum
CA-125 levels may be elevated in seminal vesicle carcinoma
and may correlate with treatment response [6,7].
For local disease, surgery can allow long-term survival
if there is no residual disease [1]. Radiotherapy has a role
in the adjuvant setting if there are positive resection
margins following surgery [1,6].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Histopathology image of seminal vesicle
adenocarcinoma. Low power hematoxylin and eosin stain, ×4
objective, ×40 magnification, showing adenocarcinoma arising from
the seminal vesicle (bottom right of picture).
Lote et al. Journal of Medical Case Reports 2013, 7:59 Page 2 of 4
http://www.jmedicalcasereports.com/content/7/1/59Because it is often detected late, adenocarcinoma of
the seminal vesicles is documented to have a poor
prognosis, with the majority of patients developing
metastatic disease, most commonly in the prostate, blad-
der and rectum [2]. The lung may be a site of distant
metastasis [1,6].
Currently there is no standard treatment for metastatic
adenocarcinoma of the seminal vesicles. The limited re-
ports of treatment with chemotherapy (with regimes in-
cluding 5-fluorouracil plus leucovorin plus oxaliplatin)
show that it has, at most, a modest benefit [1,2,6]. Hor-
monal (anti-androgenic) therapy appears slightly more
promising, with some reports of patients surviving >24
months [1]. Treating with a combination of chemother-
apy plus anti-androgenic therapy may have a role and
has been reported in one case to give a time of 16
months until disease relapse.
The association between malignancy and an increased
risk of autoimmune vasculitis has been demonstrated in
a number of malignancies [8], but to date there have
been no documented cases of adenocarcinoma of the
seminal vesicles associated with antineutrophil cytoplas-
mic antibody (ANCA) vasculitis.
We describe the case of a 55-year-old man with adeno-
carcinoma of the seminal vesicles who subsequently
developed cytoplasmic ANCA vasculitis requiring intensive
immunosuppression and renal dialysis.
Case presentation
A 55-year-old Caucasian man presented with an episode
of hemospermia. Our patient had a complex urological
history with bilateral inguinal hernias and undescended
testes as a child. At the age of 11 years he underwent a
right orchidopexy; but the left intra-abdominal testis
could not be located during the operation. At the age of
26 years, our patient presented with a large mass in his
abdomen, which was removed surgically and confirmed
as a testicular cancer arising within an intra-abdominal
testis. Postoperative treatment with cisplatin-based com-
bination chemotherapy was delivered and regular check-
ups showed no evidence of disease relapse.
Our initial investigations for hemospermia included a
cystoscopy, which revealed a 9cm mass present within
his bladder. The result of a biopsy of this mass was sug-
gestive of adenocarcinoma of the seminal vesicle, be-
cause the tumor appeared to arise from the seminal
vesicle epithelium. Computed tomography imaging re-
vealed no evidence of metastatic spread. His serum
prostate-specific antigen level was normal at presenta-
tion, but his serum CA-125 was 783kU/L. Following
diagnosis, a referral was made to Charing Cross Hospital
for specialist surgical input, resulting in a radical
cystoprostatectomy and orchidectomy (required for local
disease clearance) with the formation of an ileal conduit.Histopathology confirmed the diagnosis of adenocar-
cinoma of the seminal vesicle (Figure 1) with immuno-
histochemical studies positive for CK-7 and CA-125,
while staining for prostate-specific antigenand CK-20
was negative. The tumor was noted to be widely infiltra-
tive, involving the bladder, perivesical fat, prostate,
prostatic urethra and ductus deferens, with additional
pelvic lymph node metastases and a positive biopsy from
an inoperable peritoneal deposit.
In view of the biopsy-proven distant metastasis (the
peritoneal deposit), adjuvant radiotherapy was consid-
ered inappropriate and the initial management was of
expectant observation. After three months observation,
updated imaging demonstrated disease progression with
malignant lymphadenopathy in his pelvis and a recur-
rence of the intra-peritoneal nodule combined with a
rising CA-125 level.
Androgen withdrawal was commenced using goserelin,
but after an initial response of five months, the tumor
demonstrated evidence of progression with rising CA-
125 levels and enlarging lymphadenopathy. Despite the
serological and radiological progression, our patient
remained asymptomatic and a decision regarding the
role of chemotherapy treatment in disease palliation was
deferred. Approximately six weeks later, our patient
presented as an emergency with a short history of nau-
sea, vomiting and diarrhea. The admission investigations
showed his previously normal creatinine levels to now
be elevated at 537μmol/L and urine testing revealed pro-
teinuria >300mg/dL and hematuria with red cell casts.
Imaging did not demonstrate an obvious cause for this
rise in creatinine: ultrasound showed no hydronephrosis
or evidence of obstruction, and computed tomography
continued to show enlarging abdominal lymphadenopathy
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place six weeks earlier.
A renal biopsy (Figure 2) showed pauci-immune
crescentic glomerulonephritis with a segmental glomeru-
lar necrosis suggestive of ANCA-associated disease. A
serum ANCA screen was ANCA IIF positive with a
cytoplasmic ANCA pattern, while proteinase 3 and
myeloperoxidase antibodies were negative.
Renal replacement therapy (hemodialysis) and im-
munosuppressive therapy was commenced with prednis-
olone, cyclophosphamide and rituximab but his renal
function did not significantly recover. His glomerular fil-
tration rate remained less than 10mL/min. A repeated
renal biopsy performed in July 2011 after three months
of therapy showed glomerular and tubulointerstitial scar-
ring secondary to ANCA-mediated glomerulonephritis
but no active ANCA-mediated disease.
An updated computed tomography scan performed at
this point demonstrated significant tumor progression,
with new sites of disease in his liver, bones and adrenal
glands. In view of these findings and the challenges of
delivering chemotherapy while on dialysis, attempts at
disease palliation with chemotherapy were withheld. Our
patient was referred to our community palliative care
team for end-of-life care and died at home two months
later.Discussion
Adenocarcinoma of the seminal vesicles is a rare diagno-
sis and this case is more unusual in that our patient had
previously had chemotherapy treatment for advanced
testicular cancer and went on to develop severe ANCA
vasculitis when diagnosed with metastatic seminal
vesicle cancer.Figure 2 Histopathology image showing antineutrophil
cytoplasmic antibody vasculitis. Renal biopsy showing glomerulus
with circumferential cellular crescent.There is considerable evidence indicating that the sur-
vivors of chemotherapy treatment develop an enhanced
risk of developing a second malignancy. A number of
papers have indicated that the risk of developing a fur-
ther solid tumor is in the order of one in three (com-
pared with around one in five in the general population)
and this increased incidence becomes apparent approxi-
mately five years after treatment [9,10]. For a series of
40,576 patients, the most common solid tumor second
malignancies for men previously treated for testicular
cancer were bladder and stomach cancers, but there
were no reported cases of adenocarcinoma of the sem-
inal vesicles. As a result, it is unclear if in our case the
seminal vesicle malignancy was a true ‘second’ malig-
nancy or simply a rare unlinked event.
The link between malignancy and vasculitis is well de-
scribed but the etiology remains unclear [11]. It is be-
lieved to involve the abnormal production of proteins
that bind to endothelial walls, molecular mimicry, and
also defective apoptosis [12]. The most common malig-
nancies linked to the development of vasculitis are
hematological malignancies and lung cancer. Urological
malignancies are less commonly linked with this event [11].
In our patient, the vasculitis became clinically evident
approximately nine months after the diagnosis of meta-
static seminal vesicle cancer and was linked to the pres-
ence of ANCA IIF autoantibodies with a cytoplasmic
ANCA pattern. The mechanism of the development of
ANCA vasculitis in cancer remains unclear, but several
studies confirm that malignancy is associated with
ANCA vasculitis [13].
The standard management of vasculitis is to use
powerful immunosuppression combined with renal re-
placement therapy. A review of the literature suggests that
ANCA vasculitis is more difficult to treat in patients with
malignancy, as the vasculitis may be refractory to standard
therapy. Resolution of the vasculitis is related to successful
treatment of the underlying malignancy [14].
The development of chronic or recurrent vasculitis
may represent an underlying malignancy. More import-
antly, the appearance of vasculitis can suggest recur-
rence or progression of a tumor. The overall outcomes
for patients with severe vasculitis and malignancy are
poor, with the most important predictor of a better
prognosis being response of the underlying malignancy
to treatment. Further large-scale studies are needed to
evaluate the associations and interactions between vas-
culitis and malignancy [14].
In our patient, there was little scope to treat the
underlying malignancy and the benefits for immunosup-
pression were limited because of the requirement for
on-going dialysis. However, our case illustrates that
autoimmune vasculitis can occur in any patient with ma-
lignancy. We recommend an early referral to the renal
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diagnosis and more successful management of these rare
events.
Conclusions
Adenocarcinoma of the seminal vesicles is a rare diagnosis
and may subsequently lead to cytoplasmic ANCA vasculitis
requiring intensive immunosuppression and renal dialysis.
Appropriate subspecialty referral is warranted.
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